Cargando…

The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes

Ellipticine is a DNA-damaging agent acting as a prodrug whose pharmacological efficiencies and genotoxic side effects are dictated by activation with cytochrome P450 (CYP). Over the last decade we have gained extensive experience in using pure enzymes and various animal models that helped to identif...

Descripción completa

Detalles Bibliográficos
Autores principales: Stiborová, Marie, Černá, Věra, Moserová, Michaela, Mrízová, Iveta, Arlt, Volker M., Frei, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307247/
https://www.ncbi.nlm.nih.gov/pubmed/25547492
http://dx.doi.org/10.3390/ijms16010284
_version_ 1782354429288120320
author Stiborová, Marie
Černá, Věra
Moserová, Michaela
Mrízová, Iveta
Arlt, Volker M.
Frei, Eva
author_facet Stiborová, Marie
Černá, Věra
Moserová, Michaela
Mrízová, Iveta
Arlt, Volker M.
Frei, Eva
author_sort Stiborová, Marie
collection PubMed
description Ellipticine is a DNA-damaging agent acting as a prodrug whose pharmacological efficiencies and genotoxic side effects are dictated by activation with cytochrome P450 (CYP). Over the last decade we have gained extensive experience in using pure enzymes and various animal models that helped to identify CYPs metabolizing ellipticine. In this review we focus on comparison between the in vitro and in vivo studies and show a necessity of both approaches to obtain valid information on CYP enzymes contributing to ellipticine metabolism. Discrepancies were found between the CYP enzymes activating ellipticine to 13-hydroxy- and 12-hydroxyellipticine generating covalent DNA adducts and those detoxifying this drug to 9-hydroxy- and 7-hydroellipticine in vitro and in vivo. In vivo, formation of ellipticine-DNA adducts is dependent not only on expression levels of CYP3A, catalyzing ellipticine activation in vitro, but also on those of CYP1A that oxidize ellipticine in vitro mainly to the detoxification products. The finding showing that cytochrome b(5) alters the ratio of ellipticine metabolites generated by CYP1A1/2 and 3A4 explained this paradox. Whereas the detoxification of ellipticine by CYP1A and 3A is either decreased or not changed by cytochrome b(5), activation leading to ellipticine-DNA adducts increased considerably. We show that (I) the pharmacological effects of ellipticine mediated by covalent ellipticine-derived DNA adducts are dictated by expression levels of CYP1A, 3A and cytochrome b(5), and its own potency to induce these enzymes in tumor tissues, (II) animal models, where levels of CYPs are either knocked out or induced are appropriate to identify CYPs metabolizing ellipticine in vivo, and (III) extrapolation from in vitro data to the situation in vivo is not always possible, confirming the need for these animal models.
format Online
Article
Text
id pubmed-4307247
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-43072472015-02-02 The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes Stiborová, Marie Černá, Věra Moserová, Michaela Mrízová, Iveta Arlt, Volker M. Frei, Eva Int J Mol Sci Review Ellipticine is a DNA-damaging agent acting as a prodrug whose pharmacological efficiencies and genotoxic side effects are dictated by activation with cytochrome P450 (CYP). Over the last decade we have gained extensive experience in using pure enzymes and various animal models that helped to identify CYPs metabolizing ellipticine. In this review we focus on comparison between the in vitro and in vivo studies and show a necessity of both approaches to obtain valid information on CYP enzymes contributing to ellipticine metabolism. Discrepancies were found between the CYP enzymes activating ellipticine to 13-hydroxy- and 12-hydroxyellipticine generating covalent DNA adducts and those detoxifying this drug to 9-hydroxy- and 7-hydroellipticine in vitro and in vivo. In vivo, formation of ellipticine-DNA adducts is dependent not only on expression levels of CYP3A, catalyzing ellipticine activation in vitro, but also on those of CYP1A that oxidize ellipticine in vitro mainly to the detoxification products. The finding showing that cytochrome b(5) alters the ratio of ellipticine metabolites generated by CYP1A1/2 and 3A4 explained this paradox. Whereas the detoxification of ellipticine by CYP1A and 3A is either decreased or not changed by cytochrome b(5), activation leading to ellipticine-DNA adducts increased considerably. We show that (I) the pharmacological effects of ellipticine mediated by covalent ellipticine-derived DNA adducts are dictated by expression levels of CYP1A, 3A and cytochrome b(5), and its own potency to induce these enzymes in tumor tissues, (II) animal models, where levels of CYPs are either knocked out or induced are appropriate to identify CYPs metabolizing ellipticine in vivo, and (III) extrapolation from in vitro data to the situation in vivo is not always possible, confirming the need for these animal models. MDPI 2014-12-25 /pmc/articles/PMC4307247/ /pubmed/25547492 http://dx.doi.org/10.3390/ijms16010284 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Stiborová, Marie
Černá, Věra
Moserová, Michaela
Mrízová, Iveta
Arlt, Volker M.
Frei, Eva
The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes
title The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes
title_full The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes
title_fullStr The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes
title_full_unstemmed The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes
title_short The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes
title_sort anticancer drug ellipticine activated with cytochrome p450 mediates dna damage determining its pharmacological efficiencies: studies with rats, hepatic cytochrome p450 reductase null (hrn™) mice and pure enzymes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307247/
https://www.ncbi.nlm.nih.gov/pubmed/25547492
http://dx.doi.org/10.3390/ijms16010284
work_keys_str_mv AT stiborovamarie theanticancerdrugellipticineactivatedwithcytochromep450mediatesdnadamagedeterminingitspharmacologicalefficienciesstudieswithratshepaticcytochromep450reductasenullhrnmiceandpureenzymes
AT cernavera theanticancerdrugellipticineactivatedwithcytochromep450mediatesdnadamagedeterminingitspharmacologicalefficienciesstudieswithratshepaticcytochromep450reductasenullhrnmiceandpureenzymes
AT moserovamichaela theanticancerdrugellipticineactivatedwithcytochromep450mediatesdnadamagedeterminingitspharmacologicalefficienciesstudieswithratshepaticcytochromep450reductasenullhrnmiceandpureenzymes
AT mrizovaiveta theanticancerdrugellipticineactivatedwithcytochromep450mediatesdnadamagedeterminingitspharmacologicalefficienciesstudieswithratshepaticcytochromep450reductasenullhrnmiceandpureenzymes
AT arltvolkerm theanticancerdrugellipticineactivatedwithcytochromep450mediatesdnadamagedeterminingitspharmacologicalefficienciesstudieswithratshepaticcytochromep450reductasenullhrnmiceandpureenzymes
AT freieva theanticancerdrugellipticineactivatedwithcytochromep450mediatesdnadamagedeterminingitspharmacologicalefficienciesstudieswithratshepaticcytochromep450reductasenullhrnmiceandpureenzymes
AT stiborovamarie anticancerdrugellipticineactivatedwithcytochromep450mediatesdnadamagedeterminingitspharmacologicalefficienciesstudieswithratshepaticcytochromep450reductasenullhrnmiceandpureenzymes
AT cernavera anticancerdrugellipticineactivatedwithcytochromep450mediatesdnadamagedeterminingitspharmacologicalefficienciesstudieswithratshepaticcytochromep450reductasenullhrnmiceandpureenzymes
AT moserovamichaela anticancerdrugellipticineactivatedwithcytochromep450mediatesdnadamagedeterminingitspharmacologicalefficienciesstudieswithratshepaticcytochromep450reductasenullhrnmiceandpureenzymes
AT mrizovaiveta anticancerdrugellipticineactivatedwithcytochromep450mediatesdnadamagedeterminingitspharmacologicalefficienciesstudieswithratshepaticcytochromep450reductasenullhrnmiceandpureenzymes
AT arltvolkerm anticancerdrugellipticineactivatedwithcytochromep450mediatesdnadamagedeterminingitspharmacologicalefficienciesstudieswithratshepaticcytochromep450reductasenullhrnmiceandpureenzymes
AT freieva anticancerdrugellipticineactivatedwithcytochromep450mediatesdnadamagedeterminingitspharmacologicalefficienciesstudieswithratshepaticcytochromep450reductasenullhrnmiceandpureenzymes